Skip to main content

Advertisement

Table 2 Clinical characteristics of asthmatic children before, 3 and 6 months after inhaled corticosteroid therapy

From: Inhaled corticosteroid treatment for 6 months was not sufficient to normalize phagocytosis in asthmatic children

Parameters Before 3 months 6 months Test p
PEF (%) (mean±SD)     ANOVA
mPA 81.2±17.3 90.6±23.6 99.2±18.4 p < 0.05*
MPA 75.6±15.3 79.3±16.8 86.3±18.3 p < 0.05*
SPA 65.6±12.0 72.8±17.0 77.9±19.8 p > 0.05
BMI (Kg/m2) (mean±SD)     
mPA 51.9±34.3 45.2±32.2 43.4±37.5 Kruskal-Wallis p>0.05
MPA 47.4±31.2 50.5±31.5 50.0±30.5
SPA 63.7±32.5 61.8±29.6 63.2±29.5
ACT n (%)     
mPA     
≥25 0/23 (0%) 1/23 (4.3%) 4/22 (18.2%) Chi-square
20-24** 11/23 (47.8%) 19/23 (82.6%) 16/22 (72.7%) p<0.05
<20*** 12/23 (52.2%) 3/23 (13.0%) 2/22 (9.1%)  
MPA     
≥25 0/20 0%) 1/20 (5%) 3/20 (15%) Chi-square
20-24** 2/20 (10%) 7/20 (35%) 10/20 (50.0%) p<0.05
<20*** 18/20 (90%) 12/20 (60%) 7/20 (35.0%)  
SPA     
≥25 0/14 (0%) 0/14 (0%) 0/14 (0%) Chi-square
20-24 2/14 (14.3%) 3/14 (21.4%) 4/14 (28.6%) p>0.05
<20 12/14 (85.7%) 11/14 (78.57%) 10/14 (71.4%)
  1. PEF Peak Expiratory Flow, BMI Body Mass Index (percentile), ACT Asthma Control Test, mPA mild persistent asthma, MPA moderate persistent asthma, SPA severe persistent asthma, * 6 m > before ** 3 m and 6 m > before *** 3 m and 6 m < before.